Request a sponsored account
If your institution has a site license, you may be eligible for a sponsored account.
Enter your organization-affiliated email address below to request or renew your sponsored account.
Enter your organization-affiliated email address below to request or renew your sponsored account.
Latest Stories
Clinical
Jenna Scott was 29, seven months pregnant, and suddenly, feeling very sick.
Obituary
Maura L. Gillison, MD, PhD, a medical oncologist and molecular epidemiologist whose work changed the standard of care for head and neck cancer by distinguishing human papillomavirus-positive from HPV-negative disease and thereby guiding diagnosis, treatment and prevention, died on June 21.
Trials & Tribulations
I performed my first colonoscopy as a board-certified gastroenterologist more than 20 years ago, at a time when the procedure was firmly established as the “gold standard” for colorectal cancer screening.
Trials & TribulationsMore than 50 million Americans remain unscreened for colon cancer
More than 50 million Americans remain unscreened for colon cancer
New guidelines offer another option
For decades, we have faced a central challenge in colorectal cancer screening. One in three eligible Americans—over 50 million people—remain unscreened despite established methods like colonoscopy or stool-based tests existing for decades. This gap persists even though early detection saves lives, and even as colorectal cancer is now the number one cancer killer for Americans under 50.
Cancer Policy
The American Association for Cancer Research is urging the White House Office of Management and Budget to rescind its recent proposed rule that would give the administration unprecedented political control over government-funded science.
Cancer Policy
The Centers for Disease Control and Prevention has published an updated version of the charter for the Advisory Committee on Immunization Practices.
Cancer Policy
Delays in processing of U.S. visas are keeping foreign born resident physicians from joining U.S. residency programs, which began on July 1, a group of more than 20 medical societies said.
Cancer Policy
FDA is allowing ZYN nicotine pouches, a tobaccoless product that has soared in popularity since in recent years, to make the claim that its products are safer than cigarettes.
Cancer Policy
Starting on July 1, medical students will be precluded from borrowing more than $50,000 per year in federal direct unsubsidized loans.
In Brief
David Gius assumed the role of director of the University of Cincinnati Cancer Center, effective July 1.
In Brief
The Northwell Cancer Institute announced the opening of its renovated Queens Radiation Center in Queens, New York City.
Clinical Roundup
MammaPrint + BluePrint can help identify a subset of patients with hormone receptor positive, HER2-negative early-stage breast cancer most likely to benefit from anthracycline-based chemotherapy, according to the results of the prospective FLEX Study (NCT03053193).
Clinical Roundup
As people continue to live longer and the survival rate of cancer diagnoses increases, researchers from VCU Massey Comprehensive Cancer Center decided to lead a multi-decade analysis studying the rates of subsequent primary cancers, which are new cancers unrelated to the original diagnosis.
Clinical Roundup
An RNA-modifying enzyme linked to cancer and neurological disorders selects its targets by recognizing specific RNA shapes and sequences, according to a study by UT Southwestern Medical Center researchers.
Clinical Roundup
Researchers at Mayo Clinic have uncovered a previously hidden step in how the immune system prepares to fight cancer, a discovery that could help scientists develop more effective and longer-lasting cancer immunotherapies.
Clinical Roundup
A study led by researchers at NYU Langone Health shows how blood cancer cells enter the lungs, damage tissue, and cause severe breathing problems.
Clinical Roundup
The Alliance for Clinical Trials in Oncology has launched a new national study to see if an immune-boosting drug can help keep early-stage lung cancer from coming back after surgery.
Clinical Roundup
The Multiple Myeloma Research Foundation announced that the first patient has been enrolled in the groundbreaking Horizon Two clinical trial that aims to identify the best treatments and treatment combinations for patients with high-risk, newly diagnosed multiple myeloma.
Clinical Roundup
OST-HER2, together with palliative radiation therapy, increased median overall survival time in treated dogs from 159 days vs. 124 days in the RT-alone control group (p = 0.0237), according to the results of phase II clinical canine trial. The treatment was aimed at preventing amputation in frontline canine osteosarcoma.
Clinical Roundup
High patient volume is the leading driver of burnout in cancer and infusion centers, outpacing inadequate staffing, according to LeanTaaS’s “State of Cancer Centers” report.
Drugs & Targets
FDA’s Oncology Center of Excellence released its 2025 Annual Report.
Drugs & Targets
FDA approved Trodelvy (sacituzumab govitecan-hziy), a first-in-class Trop-2-directed antibody-drug conjugate, for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer.
Drugs & Targets
FDA approved Tregzi, the first regulatory T (Treg) cell-based immunotherapy for improving chronic graft-versus-host disease-free survival in adult patients with blood cancers undergoing allogeneic hematopoietic stem cell transplantation.
Drugs & Targets
FDA has approved expanded use of Casgevy (exagamglogene autotemcel) for the treatment of people ages 2 years and older with either sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.
NCI Trials
The National Cancer Institute approved the following clinical research studies last month.
Podcast
In this week’s episode of The Cancer Letter Podcast, Paul Goldberg, editor and publisher of The Cancer Letter, and Sara Willa Ernst, reporter, break down HHS’ latest vision for the future: Operation Trailblazer.
The Directors
How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.
Regulatory News
HHS earlier this week rolled out a cluster of initiatives related to simplifying clinical trials, presenting these measures as a government-wide effort to maintain America’s leadership in early-stage drug development.
Obituary
The world of cancer research has lost one of its brightest and gentlest stars, Joseph F. Fraumeni, Jr., MD, the founding director of NCI’s Division of Cancer Epidemiology and Genetics within the Intramural Research Program of the National Institutes of Health.
Obituary
Some lives leave their mark not only on the people who loved them, but also on the very places where others come to seek hope. Karen Haight Huntsman’s was such a life.
In the Archives
When Robert Mayer was only a few years out of residency, in the 1970s, he signed on as an investigator of the NCI-supported Gastrointestinal Tumor Study Group, which conducted research into colorectal, gastric, and pancreatic cancers.
Cancer Policy
An FDA advisory panel has recommended approval of Moderna’s mRNA-based flu vaccine, mFlusiva, for adults ages 50-64, and adults 65 and older, if a specific condition is met.
Cancer Policy
Democratic leaders of the House Committee on Energy and Commerce are urging NIH Director Jay Bhattacharya to voice objections to a proposed rule from the Office of Management and Budget that would give the administration unprecedented political control over government-funded science.
In Brief
Dana-Farber Cancer Institute announced the name of its 300-bed, freestanding cancer hospital, which is now under construction and will span 450,000 square feet across 10 inpatient floors: the Lavine Bekenstein Cancer Hospital. The building is expected to open in 2031.
In Brief
The Medical College of Wisconsin announced a $27 million gift from Tim and Barbara Michels and the Michels Family Foundation to the MCW Cancer Center. This represents the largest personal gift ever to the MCW Cancer Center.
In Brief
Kevin Becker was named the associate chief for the MUSC Health Oncology Integrated Center of Clinical Excellence.
In Brief
RWJBarnabas Health and Rutgers Cancer Institute have opened the Melchiorre Cancer Center at Cooperman Barnabas Medical Center. The cancer center, located on the campus of Cooperman Barnabas Medical Center in Livingston, is a five-story, 137,000-square-foot, $225 million, outpatient facility for oncology services.
In Brief
Memorial Sloan Kettering Cancer Center broke ground on the forthcoming inpatient facility called the Kenneth C. Griffin Pavilion in New York City.
In Brief
City of Hope broke ground for a new Pathology and Radiation Oncology Building at its Duarte campus.
In Brief
Natasha Martin, professor and vice chief of Global Public Health in the Division of Infectious Diseases and Global Public Health at UC San Diego School of Medicine, has been awarded a five-year, $5.6 million Avant-Garde Award from the National Institute on Drug Abuse.
In Brief
Project Purple has awarded a $375,000 Research Recovery Grant to researchers at the University of Texas MD Anderson Cancer Center to continue critical pancreatic cancer research.
In Brief
The Lymphoma Research Foundation has awarded 24 research grants totaling $3.9 million to support investigations to improve the diagnosis and treatment of lymphoma.
In Brief
Fred Hutch Cancer Center announced eight recipients of this year’s Dr. Eddie Méndez Scholar Award. The annual award recognizes the work of exceptional early-career scientists who are studying cancer, infectious diseases and basic sciences.
Funding Opportunities
Historically, the research initiatives of the Foundation for AIDS Research (amfAR) have focused on finding a cure for HIV. Four decades of HIV research have reshaped our understanding of the immune system, and insights from HIV have been leveraged in adjacent fields, including cancer immunology. Innovation can be bi-directional and reciprocal. Seminal findings in cancer immunology have also furthered understanding of HIV biology.
Clinical Roundup
The American Association for Cancer Research released its Cancer Disparities Progress Report 2026, an analysis of the unequal burden of cancer in the United States.
Clinical Roundup
Sigvotatug vedotin, an integrin beta-6 directed antibody-drug conjugate, did not show a statistically significant improvement in the primary endpoint of overall survival, compared to docetaxel, according to the results of the phase III SigVie-002 study (previously known as Be6A Lung-01).
Clinical Roundup
Mezigdomide, carfilzomib, and dexamethasone demonstrated a >50% reduction in the risk of disease progression or death in patients with relapsed or refractory multiple myeloma compared to carfilzomib and dexamethasone, according to the results of the SUCCESSOR-2 phase III trial.
Clinical Roundup
A simulation method, recreating operations inside a computer and testing countless possible improvements, may reduce cancer treatment times, according to a study conducted by researchers at Rutgers Cancer Institute and Rutgers Business School.
Clinical Roundup
Researchers at Moffitt Cancer Center have published a case study highlighting the potential optimization of the TAMP, or trans-arterial micro-perfusion, procedure with RenovoCath to deliver intra-arterial gemcitabine (a commonly used chemotherapy) directly near a tumor (rather than traditional systemic IV administration) in a patient with locally advanced pancreatic cancer.
Clinical Roundup
Blocking IL1RAP, a receptor that sits at a key control point in inflammatory signaling, can disrupt the tumor-driven inflammatory network that helps pancreatic cancer resist treatment, according to a study led by researchers at Sylvester Comprehensive Cancer Center.
Clinical Roundup
Researchers at Baylor College of Medicine and collaborating institutions have discovered how immune cells called neutrophils can help triple-negative breast cancer cells metastasize to other organs. The study found these interactions both in animal models and human samples of TNBC.
Clinical Roundup
Researchers have identified a critical biological difference in how glioblastoma develops in male and female laboratory models, pinpointing an immune pathway that fuels tumor growth only in females.
Drugs & Targets
FDA granted full approval of Tecelra (afamitresgene autoleucel) and expanded its indication to include pediatric patients 12 years of age and older with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices.
Drugs & Targets
The European Commission granted Marketing Authorization for Padcev (enfortumab vedotin), in combination with Keytruda (pembrolizumab), as neoadjuvant treatment (before surgery) and then continued after radical cystectomy as adjuvant treatment, for adults with resectable muscle-invasive bladder cancer who are ineligible for cisplatin-containing chemotherapy in the European Union.
Drugs & Targets
The European Commission approved Maviret (glecaprevir/pibrentasvir), an oral pangenotypic direct-acting antiviral therapy for the treatment of acute hepatitis C virus infection in adults and children aged 3 years and older. With this approval, Maviret is now the only treatment approved in the European Union for both acute and chronic HCV infection.
Drugs & Targets
The Ministry of Health, Labour and Welfare of Japan granted approval for Sarclisa (isatuximab) subcutaneous formulation in combination with approved standard-of-care regimens for the treatment of multiple myeloma.
Podcast
In this week's episode of The Cancer Letter Podcast, Paul Goldberg, editor and publisher, and Sara Willa Ernst, reporter, go on a trip into the world of federal health policy surrounding psychedelic medicine.
Regulatory News
Earlier this year, Joe Rogan, host of “The Joe Rogan Experience” podcast, sent a text to President Donald Trump.
Trials & Tribulations
On May 30, GRAIL reported the full results of the NHS-Galleri trial in an oral presentation at the ASCO Annual Meeting.
Trials & Tribulations
The NHS-Galleri trial presented at ASCO was the largest, prospective, randomized trial of a multicancer early detection test (MCED) to date. The study enrolled approximately 143,000 asymptomatic adults (ages 50-77) and was the first of its kind to assess clinical utility of an MCED test for cancer screening.
News Analysis
FDA has issued a draft guidance to reduce unnecessary animal testing in nonclinical safety assessments for some cancer pharmaceuticals.
Cancer Policy
An analysis by Stand up for Science found that the White House Office of Management and Budget’s recently proposed rule, “Regulation for Federal Financial Assistance,” if finalized, could result in termination of nearly 50% of active clinical research studies.
Cancer Policy
Asal SayasSen. Ed Markey (D-MA) and Sen. Amy Klobuchar (D-MN) introduced a bill that requires NIH to develop a national strategy to address the rise of cancer in younger adults.
In Brief
Ian E. Krop was named section chief of Medical Oncology and Hematology and deputy director for Clinical Affairs for Yale Cancer Center and Smilow Cancer Hospital.
In Brief
Veena Shankaran, co-director of the Hutchinson Institute for Cancer Outcomes Research at Fred Hutch Cancer Center,was awarded the newly established Lert Family Endowed Chair. A gastrointestinal cancer specialist, she is also a professor at Fred Hutch and UW Medicine.
In Brief
University of California San Diego Moores Cancer Center has received a five-year, $25 million Cancer Center Support Grant from NCI.
In Brief
Researchers from the UCLA Jonsson Comprehensive Cancer Center have been awarded a $3.2 million grant from NIH to develop advanced imaging and surgical strategies aimed at improving outcomes for patients with glioblastoma, a fast-growing and aggressive brain tumor.
In Brief
Kara Marshall, assistant professor of neuroscience and a McNair Scholar at Baylor College of Medicine, received the 2026 McKnight Scholar Award from the McKnight Endowment Fund for Neuroscience.
In Brief
The St. Jude Children’s Research Hospital Graduate School of Biomedical Sciences achieved institutional accreditation from the Southern Association of Colleges and Schools Commission on Colleges.
Clinical Roundup
The ASCERTAIN-V phase I/II clinical trial, which evaluated the first all-oral regimen of decitabine-cedazuridine plus venetoclax in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive induction chemotherapy, demonstrated favorable response rates and survival with expected myelosuppressive effects.
Clinical Roundup
Talvey (talquetamab-tgvs), a GPRC5D bispecific antibody, in combination with Darzalez Faspro (daratumumab and hyaluronidase-fihj) with or without pomalidomide demonstrated significant reduction in the risk of disease progression or death of up to 72% and clinically meaningful reduction of up to 53% in the risk of death compared to the standard regimen of Darzalez Faspro, pomalidomide, and dexamethasone in patients with relapsed/refractory multiple myeloma, according to the results of the investigational phase III MonumenTAL-3 study.
Clinical Roundup
Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase inhibitor, plus a two-year venetoclax and rituximab regimen versus venetoclax and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma reduced the risk of disease progression or death by 45% (HR=0.55 [95% CI, 0.40-0.75]; p=0.0001), according to the results of the phase III BRUIN CLL-322 trial. The study met its primary endpoint of independent review committee-assessed progression-free survival.
Clinical Roundup
Vispa-cel, an off-the-shelf CD19-targeted CAR-T cell therapy, produced durable long-term responses in patients enrolled in the ANTLER phase I clinical trial for relapsed or refractory B cell non-Hodgkin lymphoma, with the potential to bring the benefit of cell therapy to patients who lack curative options.
Clinical Roundup
An experimental antibody treatment that binds to a protein known as PCDH7 shrank tumors in preclinical models of non-small cell lung cancer, even those resistant to a targeted therapy, a study led by UT Southwestern Medical Center researchers showed. This discovery could eventually lead to a new class of drugs to treat NSCLC and potentially other cancers.
Clinical Roundup
A pilot project reveals that 84% of participants had a positive experience using a newly developed online tool created by the Alliance for Clinical Trials in Oncology called the Participant Engagement Portal. Alliance created PEP to foster direct connection between cancer researchers and the individuals who volunteer for clinical studies. The goal was to make it easier for patients and clinicians to share information, deliver trial updates, and self-report on social risk factors.
Clinical Roundup
Children and adolescents undergoing cancer treatment should no longer be encouraged to rest whenever possible.
Drugs & Targets
FDA has approved Ambelvist (gadoquatrane), an intravenous macrocyclic gadolinium-based contrast agent indicated for contrast-enhanced magnetic resonance imaging to detect and visualize lesions with abnormal vascularity in the central nervous system and non-CNS body regions in adult and pediatric patients, including term neonates.
Drugs & Targets
FDA has accepted for review Genentech’s supplemental Biologic License Application for their immunotherapy drug atezolizumab (Tecentriq) for the treatment of patients with stage 3 colon cancer with deficient deoxyribonucleic acid mismatch repair.
Drugs & Targets
FDA is warning providers about the interruptions in the supply of stereotactic breast biopsy needles because of recent supplier issues. The manufacturing disruption in supply of these devices is expected to impact patient care and may require adjustments to the clinical management of patients indicated to undergo a breast biopsy.
Podcast
This Pride Month, Peter F. Garrett appeared on The Cancer Letter Podcast to talk about what his experience during the HIV/Aids crisis has taught him about effective healthcare communication and advocacy.
The White House Office of Management and Budget has published a “Regulation for Federal Financial Assistance,” a proposed rule that seeks to fundamentally redraw the ground rules for all federally funded research. On the other side are America’s scientists who aren’t just crying foul—they are readying for a political fight.
Capitol Hill
On June 9, the House Appropriations Committee passed its version of the fiscal year 2027 spending bill for Labor, Health and Human Services, and Education.
Last week, Wafik El-Deiry, a cancer researcher at Brown University, showed up at a Senate hearing to talk about what he sees as dangers of the COVID-19 vaccine.
Trials & Tribulations
In 1989, I stood in front of the AIDS Memorial Quilt on a hot summer afternoon on the National Mall in Washington DC.
Sponsored
The oncology field is confronting three forces simultaneously.
Cancer Policy
NIH has published a request for information on its proposed policy that would cap the number of research project grants, or RPGs, for which an individual can simultaneously serve as principal investigator or multi-principal investigator.
Cancer Policy
Judge Leo Sorokin, of the U.S. District Court for the District of Massachusetts, struck down a new policy under the Trump administration that tacks on a $100,000 fee for H1-B visas, which allows foreign nationals in “specialty occupations” to live and work in the U.S. The fee was previously $5,000 to $10,000.
In Brief
Ozgur Sahin was named co-leader of the Cancer Biology & Immunology Program at MUSC Hollings Cancer Center. Sahin joins Sophie Paczesny in that role.
In Brief
Torben Schiffner has joined the Wistar Institute’s Vaccine & Immunotherapy Center.
In Brief
Valsamo (Elsa) Anagnostou, Jordan D. Berlin, and Olisaemeka Ogbue were named as the recipients of The ECOG-ACRIN Cancer Research Group annual scientific awards.
In Brief
Stanford has unveiled plans to build an integrated clinical care and research center in Redwood City, CA. The institution plans to submit its formal updated project description to the city and host informational community webinars.
In Brief
City of Hope broke ground on a new Pathology and Radiation Oncology Building designed to expand cancer treatment capacity and streamline care delivery in Los Angeles County.
In Brief
The University of Chicago was awarded $66 million in renewal funding from NCI to support the NRG Oncology Statistics and Data Management Center, which provides expertise in biostatistics, data management, and operational support for national clinical trials.
In Brief
The University of Chicago Medicine Comprehensive Cancer Center has been granted a six-year, $5 million grant from NCI.
In Brief
Tai R. (Terry) Shin established a systemwide research award at the University of Illinois, also establishing a named chair at the Cancer Center at Illinois (Urbana) and a named directorship at the University of Illinois Cancer Center (Chicago).
In Brief
Thyme Care announced the expansion of its Next Chapter Care survivorship program to more than 15,000 members, addressing a challenge that often receives less attention in cancer care: what happens after treatment ends.
In Brief
Editor and Publisher Paul Goldberg, Associate Editor Jacquelyn Cobb, Reporter Claire Marie Porter, and Director of Operations Katie Goldberg were named finalists in SPJ’s Washington D.C. Chapter’s annual Dateline Awards at the National Press Club June 9.
In Brief
The National Institute for Health Care Management Foundation has named Reporters Claire Marie Porter and Sara Willa Ernst finalists of the 2026 Trade Journalism awards.
Clinical Roundup
The phase III frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi/Minjuvi), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma or high-grade B-cell lymphoma, has produced positive results.
Clinical Roundup
One of the most detailed maps to date of meningioma—the most common brain tumor in adults—reveals how the tumor’s surrounding environment helps drive disease behavior and patient outcomes, according to new research from Mayo Clinic.
